| Host: |
Mouse |
| Applications: |
IHC-P |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Mouse monoclonal antibody anti-SMAD4 (DPC4) is suitable for use in Immunohistochemistry research applications. |
| Clonality: |
Monoclonal |
| Clone ID: |
B-8 |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG1 |
| Formulation: |
Purified antibody fraction from mouse anti-serum with 0.2% BSA and 15mM sodium azide |
| Purification: |
Purified |
| Dilution Range: |
IHC-P 1:200-1:400 |
| Storage Instruction: |
Store at 2-8°C upon receipt. |
| Immunogen: |
Amino acid 1-552 representing full length Smad4 of human origin |
| Background | Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as SMADs. Upon ligand binding, the receptors of the TGF-Beta family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD 1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4) , also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. The lack of SMAD4 expression is present in approximately 80% of cases of pancreatic adenocarcinoma, but rarely in endometrial (0%) , colorectal (0%) , ovarian (3%) , lung (0%) , breast (2%) adenocarcinomas, and malignant melanoma (4%). SMAD4 is an important marker for confirming a diagnosis of pancreatic adenocarcinoma. Patients with pancreatic adenocarcinomas with SMAD4 protein expression had significantly longer survival than SMAD4 negative patients. Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, or in 50 mM Tris buffer pH9.5, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections. Note: Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended. Control tissue Pacreatic adenocarcinoma. Staining Nuclear. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
